Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Fosifloxuridine nafalbenamide by NuCana for Metastatic Colorectal Cancer: Likelihood of Approval
Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Fosifloxuridine nafalbenamide by NuCana for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According...
Fosifloxuridine nafalbenamide by NuCana for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Fosifloxuridine nafalbenamide by NuCana for Esophageal Cancer: Likelihood of Approval
Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
Fosifloxuridine nafalbenamide by NuCana for Endometrial Cancer: Likelihood of Approval
Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Fosifloxuridine nafalbenamide by NuCana for Metastatic Melanoma: Likelihood of Approval
Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...
Fosifloxuridine nafalbenamide by NuCana for Gastric Cancer: Likelihood of Approval
Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
NUC-7738 by NuCana for Metastatic Melanoma: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
NUC-7738 by NuCana for Lymphoma: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Lymphoma. According to GlobalData, Phase II drugs...
NUC-7738 by NuCana for Solid Tumor: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
NUC-7738 by NuCana for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase...
NUC-7738 by NuCana for Lung Adenocarcinoma: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase II...
NUC-7738 by NuCana for Renal Cell Carcinoma: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase...
NUC-7738 by NuCana for T-Cell Lymphomas: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II...
NUC-7738 by NuCana for Chordoma: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Chordoma. According to GlobalData, Phase II drugs...
NUC-7738 by NuCana for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to...
Risk adjusted net present value: What is the current valuation of NuCana's Fosifloxuridine Nafalbenamide?
Fosifloxuridine Nafalbenamide is a small molecule commercialized by NuCana, with a leading Phase II program in Malignant Pleural Mesothelioma. According...